This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

5 Stocks Set to Soar on Bullish Earnings

Pacira Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

My final earnings short-squeeze candidate is biotechnology and drugs player Pacira Pharmaceuticals (PCRX), which just released numbers on Tuesday morning. This is a pharmaceutical company engaged in the development, commercialization, and manufacture of pharmaceutical products for hospitals and ambulatory surgery centers.

Pacira Pharma missed Wall Street estimates for the fourth quarter after reporting a loss of 72 cents vs. the consensus for a loss of 54 cents. Revenue was slightly better than Wall Street estimates at $4.23 million vs. the consensus of $4.05 million. The company also said that it expects to initiate the commercial launch of Exparel in the U.S. during the week of April 9. Exparel was approved by the FDA in October 2011.

The current short interest as a percentage of the float for Pacira Pharmaceuticals is pretty high at 12.6%. That means that out of the 12.08 million shares in the tradable float, 1.83 million are sold short by the bears. The bears have also been increasing their bets from the last reporting period by 2.7%, or by about 48,000 shares.

From a technical perspective, PCRX is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock has found some decent buying interest over the last two months at around $10 a share. The stock has also been making higher highs and higher lows over those two months, which is bullish price action. Now PCRX is trading within range of a big breakout trade post-earnings.

If you're bullish on PCRX, I would look for long-biased trades after its report if it can manage to break out above $12.01 to $12.10 a share with high-volume. Look for volume that registers close to or above its three-month average volume of 126,650 shares. If we get that action, I would then add to any long positions once PCRX takes out $13 a share with volume. A move over $13 will give PCRX a great chance to re-test its all-time high of $15.34 in the near future.

I would simply avoid PCRX or look for short-biased trades after its report if the stock fails to break out and then drops below $10, and its 200-day moving average of $9.68 a share with high-volume. Target a drop back towards $8.50 a share or lower if the bears hammer this down post-earnings.

To see more potential earnings short squeeze plays, including Sealy (ZZ), Family Dollar Stores (FDO) and Charming Shoppes (CHRS), check out the Earnings Short Squeeze Plays portfolio on Stockpickr.

-- Written by Roberto Pedone in Winderemere, Fla.

RELATED LINKS:



Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Windermere, Fla., is an independent trader who focuses on stocks, options, futures, commodities and currencies. He is also an outside contributor to Beconequity.com and maintains the website Maddmoney.net, which he sold to Blue Wave Advisors in 2008. Roberto studied International Business at The Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany.
6 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,985.61 +78.99 0.47%
S&P 500 1,972.83 +9.12 0.46%
NASDAQ 4,419.0340 +27.5710 0.63%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs